Substance / Medication

Recombinant human keratinocyte growth factor

Overview

Active Ingredient
palifermin
RxNorm CUI
196319
Labeler: Swedish Orphan Biovitrum AB (publ)Updated: 2025-12-17T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

No related conditions have been mapped yet. Condition-intervention linkages are derived from SNOMED CT relationships and will expand as the knowledge graph grows.

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Stimulation of human hair growth by the recombinant human keratinocyte growth factor-2 (KGF-2).
Jang Jun-Hyeog · Biotechnol Lett · 2005
PMID: 16086254Observational
Treatment of severe hemorrhagic cystitis after allogeneic stem cell transplantation with palifermin, a recombinant human keratinocyte growth factor.
Czibere Akos, Bruns Ingmar, Graef Thorsten et al. · Biol Blood Marrow Transplant · 2007
PMID: 17580267Case Report
Recombinant Human Keratinocyte Growth Factor Ameliorates Cancer Treatment-Induced Oral Mucositis on a Chip.
Ly Khanh L, Rajtboriraks May, Elgerbi Ahmed et al. · Adv Healthc Mater · 2024
PMID: 38351394OtherFull text (PMC)
Rational Design and Production of Bioactive Analogs of Recombinant Human Keratinocyte Growth Factor (rhKGF) with Reduced Aggregation Propensity.
Dastjerdeh Mansoureh Shahbazi, Yasami-Khiabani Setayesh, Boroujeni Mohammadtaghi Borjian et al. · Protein J · 2023
PMID: 36683078Other
Interactions of heparin derivatives with recombinant human keratinocyte growth factor: Structural stability and bioactivity effect study.
Kalhor Hourieh, Abolhasani Hoda, Kalhor Reyhaneh et al. · Proteins · 2023
PMID: 36424813Other
[Optimization of thebaculovirus expression system enhances the expression level of recombinant human keratinocyte growth factor-1 (hKGF-1)].
Li Shuohao, Wang Xingyang, Wu Xiaofeng et al. · Sheng Wu Gong Cheng Xue Bao · 2025
PMID: 40769548Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Recombinant human keratinocyte growth factor (substance)
SNOMED CT
417092008
UMLS CUI
C0677829
RxNorm CUI
196319
Labeler
Swedish Orphan Biovitrum AB (publ)

Clinical Data

This intervention maps to 0 entities in the Healos knowledge graph.

0
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.